DGCI Approves Emergency Use Of Zydus’s Virafin In Treating Moderate COVID-19 Infection
Mumbai: During a major development among coronovirus cases and deaths in the country, the Drugs Controller General of India or DCGI on Friday granted emergency use approval for Zydus Cadila’s Pegylated Interferon alpha-2b, ‘Virafin’, for treating moderate COVID-19 infection in adults.
According to the pharmaceutical firm, a single dose of anti-viral Virafin is administered quickly which shows significant clinical and virological improvement in moderate COVID-19 adult patients.
Pharma’s leading patients noted on their Twitter account, “91.5 per cent of patients with Pegifan had RT-PCR negative day 7.”
The firm also states that the treatment significantly reduces the hours of supplemental oxygen required for COVID-19 patients.
This news is going to bring some relief as the country is facing the second wave of the COVID-19 epidemic. India reported more than 3.32 lakh new coronavirus cases in the last 24 hours – an epidemic record.
A total of 3,32,730 new coronavirus cases reached 1,28,63,695 of India’s caseload with 24,286,000 active cases. The overall death toll is 1,86,920, including a record 2,263 new fatalities.
The national COVID-19 recovery rate has now fallen to 83.92 per cent with the case fatality rate being at 1.15 per cent. Recoveries stand at 1,36,48,159.
Follow us on Twitter, Instagram, and like us on Facebook for the latest updates and interesting stories.
